IN THE NEWS | Did you catch the story about Melbourne tradie Peter Moulding this weekend? Peter became the first patient to record a pathological complete response in metastatic #pancreaticcancer as part of our ACCENT trial. Take a look: $ATX #Amplia

$ATX | #Amplia has announced an additional confirmed partial response (PR) in the ongoing ACCENT trial, bringing the total number of confirmed PRs to 16 out of 55 patients enrolled. Read the ASX release: #pancreaticcancer #clinicaltrial

We're pleased to share that Amplia's Manager Product Development, Dr Adrian Sulistio, will be sharing our Company journey at the upcoming Pharmaceutical Development Conference in Sydney. $ATX #Amplia #clinicaltrials #pancreaticcancer #pharma #biotech

$ATX | #Amplia has received US ethics approval to initiate a Phase 2 clinical trial of narmafotinib in combination with FOLFIRINOX chemotherapy for advanced pancreatic cancer patients. Read the ASX release:  #biotech #pancreaticcancer #clinicaltrial #ASX

$ATX | #Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release: #pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX

Did you catch this summary of the latest results from Amplia's ACCENT clinical trial in Small Caps this week? Take a look: $ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #innovation.

#Amplia has made headlines today following the announcement of a “pathological complete response” in an advanced #pancreaticcancer patient today. Biotech journalist Tim Boreham noted that Amplia shares had soared almost 50% following the news. Take a look:

$ATX UPDATE | #Amplia has today announced that a patient from ACCENT clinical trial in advanced #pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the #ASX release:

#Amplia has been featured in Bioshares, in an update on our clinical trials program, including our ACCENT study and our upcoming US FOLFIRINOX trial. $ATX #pancreaticcancer #clinicaltrial #cancer #innovation #pharma #biotech #invest

The $ATX team is delighted to be attending the #Biomelbwomen lunch today ✨. “We are so proud to bring this vibrant ecosystem together. May we continue to listen, to learn and to lead - and to uplift every voice in the room.” - BioMelbourne Network CEO, Karen Parr #biotech #STEM

MILESTONE ACHIEVED | #Amplia has announced 15 confirmed partial responses in the ACCENT trial, demonstrating narmafotinib in combination with chemotherapy is superior to chemotherapy alone in advanced #pancreatic cancer. Read the ASX release: $ATX

$ATX NEWSLETTER | Our May Investor Newsletter is now live, featuring an ACCENT trial update, global FAK validation, a Q&A with Dr Adrian Sulistio on our CMC activities. Take a look: #Amplia #innovation #biotech #oncology #pancreaticcancer #clinicaltrial

We’re proud of our COO Rhiannon Jones and her son Edward who ran in the Mother's Day Classic this weekend. As Rhiannon noted, "It's poignant to see the tributes to loved ones and a good reminder why we do what we do." To donate: $ATX #Amplia #cancer

APPOINTMENT | #Amplia has today announced the appointment of experienced oncologist and clinical trial specialist Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer. Read the ASX Release: $ATX #pharma #clinicaltrials #cancer #oncology #leadership

$ATX | Amplia Therapeutics has today released its Appendix 4C Cash Flow Report for the quarter ending 31 March 2025. Read the ASX release: $ATX #Amplia #innovation #pancreaticcancer #clinicaltrial #pharma #biotech

$ATX | A poster highlighting key data from Amplia's ongoing ACCENT trial is being presented today at AACR Annual Meeting  - the premier forum for cancer research. View the poster: #Amplia #cancer #pancreaticcancer #clinicaltrial #pharma #research #AACR2025

Data from our ongoing ACCENT trial will be presented at next week's American Association of Cancer Research (AACR) Meeting by Amplia's Director of Translational Science, Dr Terrie-Anne Cock. $ATX #Amplia #pancreaticcancer #research #FAK #cancer #AACR2025

$ATX | #Amplia has today announced that trial initiation activities for the planned pancreatic cancer trial in the US have begun. Read the ASX release: #pancreaticcancer #clinicaltrial #drugdiscovery #innovation #cancertreatment

$ATX UPDATE | #Amplia CEO & MD Dr Chris Burns and COO Dr Rhiannon Jones discuss the latest clinical data from the ACCENT trial , the Company’s poster presentation at the AACR annual meeting, and the Company’s upcoming presence at BioKorea. Take a look:

UPDATE | #Amplia has today reported updated data from the Company’s ongoing ACCENT trial. The latest analysis shows 13 confirmed partial responses (PRs) have been observed to date. Read the ASX release: $ATX #ASX #pancreaticcancer #clinicaltrial